Literature DB >> 35599280

Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.

Neethu Jose1, Anjana Joel2, Rajesh Joseph Selvakumar3, Jebakarunya Ramireddy1, Ajoy Oommen John4, Josh Thomas Georgy4, Ashish Singh4, Thomas Samuel Ram1.   

Abstract

BACKGROUND: The administration of 5-fluorouracil (5FU) in the treatment of gastrointestinal (GI) malignancies is associated with common side effects such as mucositis, diarrhoea, and myelosuppression, which are easily managed with supportive measures and dose adjustments. Cardiotoxicity and neurotoxicity are rare but reversible side effects of 5-FU and are treated with withdrawal of the drug and conservative measures. The presenting symptoms of 5-FU-induced leukoencephalopathy are often confusing and pose a diagnostic dilemma in routine clinical practice.
METHODS: We report a series of five patients with GI malignancies who developed 5-FU-induced leukoencephalopathy.
RESULTS: All (n = 5) had Naranjo scores of 6-7, predictive of 5-FU-related adverse effects, with clinical and radiological findings suggestive of 5-FU-induced encephalopathy as described in prior literature. The median time to onset of symptoms from initiation of 5FU was 3 days (range: 2-4 days). All patients improved after conservative management with complete neurological recovery.
CONCLUSION: Prompt recognition of this rare yet severe adverse effect of 5-FU-based chemotherapy aids early withdrawal of the offending agent (5-FU) and timely initiation of supportive measures and helps plan alternative oncological interventions.
© 2022. The Author(s).

Entities:  

Keywords:  5-FU; 5-fluorouracil; Fluoropyrimidines; Magnetic resonance imaging (MRI); Toxic leukoencephalopathy

Mesh:

Substances:

Year:  2022        PMID: 35599280     DOI: 10.1186/s43046-022-00117-4

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  21 in total

1.  Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

Authors:  H Koenig; A Patel
Journal:  Arch Neurol       Date:  1970-08

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

3.  Fluorouracil-induced neurotoxicity.

Authors:  N A Pirzada; I I Ali; R M Dafer
Journal:  Ann Pharmacother       Date:  2000-01       Impact factor: 3.154

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 5.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

Authors:  André B P van Kuilenburg
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

7.  Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.

Authors:  Sonia Amin Thomas; Neveen Tomeh; Stephanie Theard
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

Review 8.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

9.  Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Authors:  G Milano; M C Etienne; V Pierrefite; M Barberi-Heyob; R Deporte-Fety; N Renée
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

10.  Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.

Authors:  Shiraz S Fidai; Aarti E Sharma; Daniel N Johnson; Jeremy P Segal; Ricardo R Lastra
Journal:  Autops Case Rep       Date:  2018-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.